The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study

G. Galatola, R. Ferraris, R. Pellerito, A. Barlotta, O. M. Umberto, T. G. Sciaretta, A. Furno, M. Mazzoni, O. Maggiore, G. Ferfoglia, C. Sategna-Guidetti, G. Castellano, A. Corso, E. Fesce, L. Snider, O. S. Anna

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To assess the prevalence of bile acid malabsorption and the efficacy of cholestyramine therapy in improving symptoms associated with this condition in patients with diarrhoric type irritable bowel syndrome. Design: Multicentre uncontrolled open prospective trial. Methods: The 7th day abdominal retention of the γ-labelled bile acid selena-homocholic acid taurine (SeHCAT) was measured in 98 patients diagnosed as suffering from irritable bowel syndrome after exclusion of organic disease. Cholestyramine was prescribed to all patients with altered SeHCAT test using a stepwise increasing dose schedule starting from 2g per day until reaching efficacy or 12g per day. Results: The overall prevalence of altered SeHCAT retention was 57.1%; in patients with faecal wet weight of more than 200 g per day the prevalence was 83%, whereas in those with faecal wet weight less than or equal to 200g per day it was 40%. There was an association between increased faecal weight and SeHCAT retention (odds ratio = 6.7, P

Original languageEnglish
Pages (from-to)533-537
Number of pages5
JournalEuropean Journal of Gastroenterology and Hepatology
Volume4
Issue number7
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'The prevalence of bile acid malabsorption in irritable bowel syndrome and the effect of cholestyramine: An uncontrolled open multicentre study'. Together they form a unique fingerprint.

Cite this